Expert Cancer Panel: Jehovah’s witness w/ multiple myeloma s/p RVD under evaluation for auto SCT

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Recorded on 5/22/2021

65-year-old Jehovah’s witness with multiple myeloma in remission after RVD under evaluation for autologous-SCT.

Summary:
- There is no contraindication for treating a patient who declines transfusions with standard induction therapy for myeloma. An erythropoietin stimulating agent may be considered if necessary. However if an ESA is used along with lenalidomide, consider escalating thromboembolic prophylaxis from aspirin to anticoagulation with a DOAC or LMH.
- Autologous stem cell transplant is not curative in myeloma, and the decision to pursue this in a patient who declines transfusions may pose a higher risk of complications, and the decision must be individualized. There are “bloodless” specialized transplant centers in the U.S. that will accommodate such patients.


At PrecisCa, we are dedicated to providing expert second opinions for cancer patients to ensure they receive the best possible care. Our videos cover a wide range of topics related to oncology, including in-depth discussions on different types of cancer, treatment options, patient stories, and the latest advancements in cancer research. Whether you're a patient, caregiver, or simply seeking to expand your knowledge, our goal is to support you on your healthcare journey.

Visit our website: https://www.PrecisCa.com for more detailed information and personalized second opinions.

Stay connected with us:
Facebook: / precisca.oncology
Twitter: https://twitter.com/precisca_?lang=en
-Instagram: / precisca_oncology
-LinkedIn: / precisca

Don't forget to subscribe to our channel for regular updates and new videos. Hit the bell icon to receive notifications every time we upload. #Oncology #CancerCare #CancerSupport #CancerResearch #Health #Healthcare #CancerTreatment #CancerAwareness #PatientCare #MedicalAdvice #PrecisCa
Category
Oncology
Be the first to comment

Up Next